LifeSci Capital downgraded Kala Pharmaceuticals (KALA) to Market Perform from Outperform and removed the firm’s price target after the company announced that its CHASE Phase 2b clinical trial of KPI-012 for the treatment of persistent corneal epithelial defect did not meet its primary endpoint and that the company plans to cease development of KPI-012 and its mesenchymal stem cell secretome platform based on the CHASE trial results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALA: